Lipids, lipophilic drugs, and oral drug delivery - Some emerging concepts

Journal of Pharmaceutical Sciences

Volumn 89, Issue 8, 2000, Pages 967-978

  Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Formulation; Lipid dose forms; Poorly water soluble drugs

Indexed keywords

LIPID;

BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG STABILITY; GASTROINTESTINAL ABSORPTION; LIPOPHILICITY; SHORT SURVEY; SOLUBILIZATION;

EID: 0033812424     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6017(200008)89:8<967::AID-JPS1>3.0.CO;2-R     Document Type: Article

References (122)

1. Lipid digestion and absorption
2. Physicochemical and physiological mechanisms for the effects of food on drug absorption: The effect of lipids and pH. Charman W.N, Porter CJH, Mithani S, Dressman JB
3. Drug, meal and formulation interactions influencing drug absorption after oral administration
4. Microemulsions
5. Microemulsions as drug delivery vehicles
6. Lipid-based vehicles for the oral delivery of poorly water-soluble drugs
7. The potential of oily formulations for drug delivery to the gastrointestinal tract
8. Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects
9. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems and recent breakthroughs
10. Hydrolysis of dietary glycerides and phosphoglycerides: Fatty acid and positional specificity of lipases and phospholipases
11. Gastric and lingual lipases
12. Structure of human pancreatic lipase
13. Intestinal synthesis, secretion and transport of lipoproteins
14. Lipid absorption: Passing through the unstirred layers, brush border membrane, and beyond
15. Intestinal lipid absorption
16. A relation between the chain length of fatty acids and slowing of gastric emptying
17. Self-emulsifying drug delivery systems: Formulation and biopharmaceutical evaluation of an investigational lipophilic compound
18. Self emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and absorption of lipophilic drugs
19. Reduced inter- and intra-individual variability in cyclosporin pharmacokinetics from a microemulsion formulation
20. Comparative bioavailability of L-688,453, a 5-α-reductase inhibitor, from a self-emulsifying drug delivery system in beagles dogs
21. Formulation of self-emulsifying drug delivery systems
22. Solubilization of hydrophilic drugs in oily formulations
23. Key issues when formulating hydrophobic drugs with lipids
24. Intestinal processing of dietary lipids
25. Lipid digestion and absorption
26. The characteristics of mixed micellar solution with particular reference to man
27. Micelle formation by bile salts
28. Physicochemical state of lipids in intestinal content during their digestion and absorption
29. The intraluminal phase of fat digestion in man: The lipid content of micellar and oil phases of intestinal content obtained during fat digestion and absorption
30. The relationship between uptake in vitro of oleic acid and micellar solubilization
31. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the mucosal cell
32. The role of micellar solubilization in lipid absorption
33. Fatty acid transfer in taurodeoxycholate mixed micelles
34. Mechanism of intestinal fatty acid uptake in the rat: The role of an acidic microclimate
35. Acidic mucin layer facilitates micelle dissociation and fatty acid diffusion
36. Human jejunal unstirred layer: Evidence for an extremely efficient luminal stirring
37. Physical-chemical behaviour of dietary and biliary lipid during digestion and absorption. 2. Phase analysis and aggregation studies of luminal lipids during duodenal fat digestion in healthy adult human beings
38. Physical-chemical behaviour of dietary and biliary lipid during digestion and absorption. 1. Phase analysis and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings
39. Fat digestion in patients with bile acid malabsorption but minimal steatorrhea
40. Lipids and oral bioavailability: Are there yet-to-be realised opportunities?
41. Biopharmaceutical studies of lipid containing oral dose forms: Relationship between drug absorption rate and digestibility of lipid vehicles
42. In vitro model for cyclosporin intestinal absorption in lipid vehicles
43. Infleunce of lipolysis on drug absorption from the gastro-intestinal tract
44. A new method for dissolution studies of liquid-filled capsules employing nifedipine as a model drug
45. Unconventional dissolution methodologies
46. Drug release from lipid based dose forms. Part 2
47. Enhanced intestinal absorption of cyclosporin in rats through reduction of particle size
48. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine
49. Determination of the pH dependent phase distribution of prostaglandin E1 in a lipid emulsion by ultrafiltration
50. Effect of oil on the level of solubilization of testosterone propionate into non-ionic oil-in-water microemulsions
51. Halofantrine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential
52. Pharmacokinetics of halofantrine in man: Effects of food and dose size
53. A physicochemical basis for the effect of food on the bioavailability of halofantrine
54. Effect of food and a monoglyceride emulsion on danazol bioavailability
55. Influence of a fat-rich meal on the pharmacokinetics of a new microemulsion formulation of cyclosproin in a crossover comparison with the market formulation
56. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion
57. Intestinal drug metabolism and antitransport processes: A potential shirft inoral drug delivery
58. Active secretion and enterocyte drug metabolism barriers to drug absorption
59. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
60. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach
61. Overlapping substrate specificity and tissue distributions of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and cancer chemotherapy
62. Interrelationships between substrates and inhibitor of human CYP3A and P-glycoprotein
63. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP 3A protein expression
64. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin A
65. Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine
66. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine
67. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4. Potential contribution to first-pass metabolism
68. Saquinavir, and HIV protease inhibitor, is transported by P-glycoprotein
69. Pharmacokinetic and biotransformation studies of terfenadine in man
70. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC-7) cell monolayers
71. The drug transporter P-glycoprotein limits the oral absorption and brain entry of HIV-1 protease inhibitors
72. Is the role of the small intestine in first-pass metabolism over-emphasized?
73. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system
74. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells
75. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans
76. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo
77. Jejunal absorption and metabolism of R/S-verapamil in humans
78. Intestinal secretion of drugs. The role of P-glycoprotein and related efflux systems in limiting oral drug absorption
79. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein
80. Inhibition of P-glycoprotein by D-α-tocopheryl polethylene glycol 1000 succinate (TPGS)
81. Grapefruit juice activates P-glycoprotein mediated drug transport
82. Lipid vehicle and formulation effects on intestinal lymphatic drug transport
83. Uptake of drugs into the intestinal lymphatics after oral administration
84. Lymphatic transport of halofantrine in the triple-cannulated anaesthetised rat model: Effect of lipid vehicle dispersion
85. The lymphatic transport of p,p-DDT and some structurally related analogs
86. Absorption and disposition of epithiosteroids. (2). Avoidance of first pass metabolism of mepitiostane by lymphatic absorption
87. Lipophilic prodrugs designed for intestinal lymphatic transport
88. Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules
89. Methodologies for assessing intestinal lymphatic transport
90. Model systems for intestinal lymphatic transport studies
91. A novel triple-cannulated conscious dog model for assessment of the absorption, enterocyte-based metabolism and lymphatic transport of candidate lipophilic drugs
92. Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion
93. Intestinal lymphatic transport is the primary absorption route for halofantrine after oral postprandial administration
94. Cardiac complications of halofantrine: A prospective study of 20 patients
95. Electro-cardiographic changes and halofantrine plasma levels during acute falciparum malaria
96. Halofantrine given with food for falciparum malaria
97. Cardiac effects of antimalarial treatment with halofantrine
98. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria
99. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator, via a formulation approach
100. Effect of short, medium and long chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats
101. Interaction of drugs with human plasma lipoproteins
102. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs
103. Lipoproteins and microemulsions as carriers of therapeutic and chemical agents
104. Drug targeting: Application of endogenous carriers for site-specific delivery of drugs
105. 50 of halofantrine against Plasmodium falciparum
106. Significance of lipoproteins in serum binding variations of amytriptyline, nortriptyline, and quinidine
107. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporine A in the blood
108. Infleunce of blood components on the tissue uptake indices of cyclosporin in rats
109. Effects of plasma lipids on blood distribution and pharmaceokinectis of cyclosporin A
110. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state
111. Differences in the lipoprotein binding of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolar lipid
112. Liposomes as carriers of antifungal drugs
113. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin
114. High cyclosporin levels after bone marrow transplantation associated with hypertriglyceredemia
115. Central nervous system toxicity after liver transplantataion
116. Effect of simvastatin on cyclosporine unbound free fraction and apparent blood clearance in heart transplant recipients
117. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients
118. High-fat meal increases in the clearance of cyclosporin
119. Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat
120. Pathogenesis and management of lipoprotein disorders